BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

18 articles for AD Brown

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT2C) receptor agonists with exquisite functional selectivity over 5-HT2A and 5-HT2B receptors.EBI
Pfizer
Ion channels as therapeutic targets: a drug discovery perspective.EBI
Pfizer
Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans.EBI
Pfizer
The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD.EBI
Pfizer
The discovery of long acting beta2-adrenoreceptor agonists.EBI
Pfizer
N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.EBI
Pfizer
Synthesis and pharmacological activity of angiotensin converting enzyme inhibitors: N-(mercaptoacyl)-4-substituted-(S)-prolines.EBI
Schering-Plough
Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles.EBI
Pfizer
Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.EBI
Pfizer
Inhalation by design: novel ultra-long-actingß(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.EBI
Pfizer
Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist.EBI
Pfizer
Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT(2C) agonists.EBI
Pfizer
7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.EBI
Pfizer
Design of selective thrombin inhibitors based on the (R)-Phe-Pro-Arg sequence.EBI
Pfizer
The discovery and optimization of benzimidazoles as selective NaEBI
Pfizer
Highly potent and selective NaEBI
Pfizer
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaEBI
Icagen
SALT AND CRYSTAL FORM OF EGFR INHIBITOR, AND COMPOSITION AND USE THEREOFBDB
Betta Pharmaceuticals